Drug intelligence / Profile preview

WHV surface antigen vaccine

Development stage: Preclinical
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Intradermal

Overview

The WHV surface antigen vaccine is an alum-adjuvanted vaccine designed to stimulate an immune response against the Woodchuck Hepatitis Virus (WHV) surface antigen. It has been studied in woodchucks with chronic WHV infection, where it was shown to break humoral and cell-mediated immune tolerance. The vaccine aims to reduce viral load, antigenaemia, and hepatic WHV DNA and RNA, inhibit the progression of chronic hepatitis, reduce chronic liver injury, and delay the onset of hepatocellular carcinoma, particularly when used in combination with antiviral therapy like clevudine.

Other names: WHsAg alum-adjuvanted vaccinewoodchuck hepatitis virus surface antigen vaccine

Targets

HBsAg (Hepatitis B surface antigen)

Beyond the preview

Go deeper on WHV surface antigen vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WHV surface antigen vaccine.

Explore the full profile